Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexborneol SCHEMBL115722 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL2784798 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL56715 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Borneol SCHEMBL9303303 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL17746906 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL23849409 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL56713 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Borneol SCHEMBL20576251 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL20576252 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL2469360 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| CN-120136674-A | Borneol derivative and application thereof in pharmacy | 浙江大学 | 2025-06-13 | — | — | CN | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4291669-A2 | ENANTIOSELECTIVE HYDROLYSIS | Technische Universität Graz (AT) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023122752-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022171652-A2 | ENANTIOSELECTIVE HYDROLYSIS | TECHNISCHE UNIVERSITÄT GRAZ (AT) | 2022-08-18 | — | — | WO | disclosed |
| EP-4043577-A1 | ENANTIOSELECTIVE HYDROLYSIS | Technische Universität Graz (AT) | 2022-08-17 | — | — | EP | disclosed |
| US-20210053999-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-02-25 | — | — | US | disclosed |
| US-20050027095-A1 | New binder combinations for highly resistant plastic paints | BAYER MATERIALSCIENCE AG (DE) | 2005-02-03 | — | — | US | disclosed |
| EP-1502926-A1 | New primer combinations for highly resistent polymer lacquers | Bayer MaterialScience AG (DE) | 2005-02-02 | — | — | EP | disclosed |
| EP-1281790-B1 | Volatile corrosion inhibitors and process for making them | EXCOR KORROSIONSFORSCHUNG GMBH (DE) | 2004-08-18 | — | — | EP | disclosed |
| US-6752934-B2 | USED IN PACKAGING OR IN STORAGE IN CLOSED SPACES FOR PROTECTION OF THE CONVENTIONAL METALS FOR USE SUCH AS IRON, CHROMIUM, NICKEL, TIN, ZINC, ALUMINUM, COPPER AND THEIR ALLOYS AGAINST ATMOSPHERIC CORROSION | EXCOR KORROSIONSFORSCHUNG GMBH (DE) | 2004-06-22 | — | — | US | disclosed |
| US-20040077817-A1 | Water-dilutable polyesters with cyclic imide and isocyanurate structure | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063852-A1 | Water-dilutable polyesters with cyclic imide structure | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004022628-A1 | WATER-DILUTABLE POLYESTERS WITH A CYCLIC IMIDE STRUCTURE | BAYER MATERIALSCIENCE AG (DE) | 2004-03-18 | — | — | WO | disclosed |
| US-20030031583-A1 | Vapor-phase corrosion inhibitors and method of preparing same | EXCOR KORROSIONSFORSCHUNG GMBH (DE) | 2003-02-13 | — | — | US | disclosed |
| EP-1281790-A1 | Volatile corrosion inhibitors and process for making them | EXCOR Korrosionsforschung GmbH (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-1991018890-A1 | BICYCLIC CHIRAL COMPOUNDS | THE BRITISH PETROLEUM COMPANY PLC (GB) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | EPHX2 2387/4885MAPT 3403/4885MAPK1 4847/4885 |
| US-20210053999-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | CBX2, BRD4, BRD3 | EPHX2 698/4885MAPT 4191/4885MAPK1 2589/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | EPHX2 2387/4885MAPT 3403/4885MAPK1 4847/4885 |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | EPHX2 2387/4885MAPT 3403/4885MAPK1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.